Cytosolic ME1 integrated with mitochondrial IDH2 supports tumor growth and metastasis.
NADPH is a pivotal cofactor that maintains redox homeostasis and lipogenesis in cancer cells and interference with NADPH production is a promising approach for treating cancer. However, how normal and cancer cells differentially exploit NADPH-producing pathways is unclear, and selective approaches to targeting NADPH are lacking. Here, we show that the assayed cancer cell lines preferentially depend on ME1-mediated NADPH production. ME1 knockdown increases intracellular ROS levels and impairs lipogenesis in cancer cells, leading to retarded proliferation and increased anoikis, while sparing normal cells. Notably, ME1 interference ultimately resulted in adaptive upregulation of mitochondrial IDH2 dependent of AMPK-FoxO1 activation to replenish the NADPH pool and mitigate cytosolic ROS. Combining ME1 ablation and IDH2 inhibition drastically reduces intracellular NADPH and prevents resistance to ME1 interference, resulting in increased apoptosis and impeded tumor growth and metastasis. This study demonstrates that cytosolic ME1 integrated with mitochondrial IDH2 is essential for tumor growth and metastasis, thereby highlighting the blockade of metabolic compensation by disrupting mitochondrial-cytosol NADPH transport as a promising approach to selectively targeting NADPH in cancer cells that rely on NADPH-driven antioxidant systems.
['Shao|Chang|C|', 'Lu|Wenjie|W|', 'Du|Ye|Y|', 'Yan|Wenchao|W|', 'Bao|Qiuyu|Q|', 'Tian|Yang|Y|', 'Wang|Guangji|G|', 'Ye|Hui|H|', 'Hao|Haiping|H|']
D003600:Cytosol D006801:Humans D008291:Malate Dehydrogenase D008928:Mitochondria D009369:Neoplasms D010084:Oxidation-Reduction
ME1 IDH2 NADPH ROS Metabolic adaptability Reductive carboxylation